CEO Pablo Cagnoni shares how the company manufactures genetically engineered red blood cells to eliminate cancer and treat autoimmune diseases.
Rubius Therapeutics is advancing its new class of cellular medicines called Red Cell Therapeutics (RCTs) — red blood cells engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent, and allogeneic cellular therapies.[Rubius Therapeutics]
Rubius is advancing its new class of cellular medicines called Red Cell Therapeutics (RCTs) — red blood cells engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent, and allogeneic cellular therapies . . .
